cme.medlearning.de - CME Logo

Literatur

  1. Haynes RB. Improving patient adherence: state of the art, with a special focus on medication taking for cardiovascular disorders. In: Burke LE, Ockene IS, eds. Compliance in health care and research. New York: Futura Publishing Co Inc, 2001; 3-21.
  2. Haynes R, Yao X, Degani A, et al. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005:CD000011.
  3. Gölz J, Rockstroh J. Compliance in der HIV-Therapie. Bremen: UNI-MED Verlag, 2001.
  4. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
  5. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32:345-356.
  6. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 2002; 54:212-220.
  7. Deutsche AIDS-Hife e.V. Compliance: Umgang mit der HIV-Therapie. Med-Info Medizinische Informationen zu HIV und AIDS 2005; September.
  8. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150:1377-1378.
  9. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150:1509-1510.
  10. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. Jama 2002; 288:455-461.
  11. British Thoracic Society, Scottisch Intercollegiate Guidelines Network. Concordance and compliance. In: British guideline on the management of asthma, 2005; 59-60.
  12. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Bmj 2001; 323:896-900.
  13. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000; 117:542-550.
  14. World Health Organization (WHO). Adherence to long-term therapies: evidence for action. Genf: (Besucht: 07.01.2008), 2003.
  15. Lindberg M, Ekstrom T, Moller M, Ahlner J. Asthma care and factors affecting medication compliance: the patient's point of view. Int J Qual Health Care 2001; 13:375-383.
  16. Scherman MH, Dahlgren LO, Lowhagen O. Refusing to be ill: a longitudinal study of patients' experiences of asthma/allergy. Disabil Rehabil 2002; 24:297-307.
  17. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6:566-573.
  18. Waeber B, Leonetti G, Kolloch R, McInnes GT. Compliance with aspirin or placebo in the Hypertension Optimal Treatment (HOT) study. J Hypertens 1999; 17:1041-1045.
  19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
  20. Kuhlmann B, Liess H. Leitlinien der DAGNÄ zur Unterstützung der Adhärenz im Rahmen einer antiretroviralen Therapie bei HIV-Infektion. 2004.
  21. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001; 161:1962-1968.
  22. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
  23. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-163.
  24. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17:377-381.
  25. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19:1111-1117.
  26. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 Suppl 2:S171-176.
  27. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS 2003; 17:169-177.
  28. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Bmj 2006; 333:15.
  29. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996; 124:984-994.
  30. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med 2003; 139:810-816.
  31. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-395.
  32. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-347.
  33. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-1088.
  34. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
  35. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 2003; 79:59-61.
  36. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids 2002; 16:269-277.
  37. Burney KD, Krishnan K, Ruffin MT, Zhang D, Brenner DE. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Arch Fam Med 1996; 5:297-300.
  38. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134:968-977.
  39. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: updating a complex medical issue. Med Care Rev 1992; 49:435-454.
  40. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? Jama 1993; 269:2779-2781.
  41. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. Aids 2004; 18:227-235.
  42. Alexander CS, Asselin JJ, Ting LS, et al. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188:541-548.
  43. Deutsche AIDS-Gesellschaft (DAIG) und Österreichische AIDS-Gesellschaft (ÖAG) in Abstimmung mit weiteren Fachgesellschaften. Antiretrovirale Therapie der HIV-Infektion. http://www.uni-duesseldorf.de/AWMF/ll/055-001.htm 2005; besucht am 06.11.2007.
  44. Deutsche Klinik für Diagnostik - Gastroenterologie/Infektiologie. Referenzwerte. 2007.
  45. Klinker H. Pharmakologische Interaktionen bei der antiretroviralen Therapie. Arzneimitteltherapie 2005; 23:80-88.
  46. Langmann P, Klinker H. Pharmakologie und Therapeutisches Drug Monitoring. In: Bogner JR, ed. Proteasehemmer in der HIV-Therapie. Bremen: UNI-MED-Verlag, 2006; 89-98.
  47. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007; 76:391-396.
  48. Flexner CW, Pham P. Drug-drug interactions tool: from the CME-certified program managing drug-drug Interactions in the changing landscape of HIV. http://clinicaloptions.com/HIV/Treatment%20Updates/Drug-Drug%20Interactions.aspx 2007; besucht am 06.11.2007.
  49. Guillaume M, et al. The pharmacokinetics of SCH 417690 when administered alone and in combination with lamivudine/zidovudine. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brasil, 2005.
  50. Guillaume M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with tenofovir. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brasil, 2005.
  51. Saltzman M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir and efavirenz in healthy volunteers. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brasil, 2005.
  52. Saltzman M, et al. Pharmacokinetics of SCH 417690 administered alone or in combination with ritonavir or lopinavir/ritonavir. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brasil, 2005.
  53. Langmann P, Klinker H, Schirmer D, Zilly M, Bienert A, Richter E. High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy. J Chromatogr B Biomed Sci Appl 1999; 735:41-50.

 Back to Top

 

Valid XHTML 1.0 Transitional